The compound used in our studies, VU595, has previously been shown to exhibit efficacy in correcting abnormal social and spatial memory phenotypes in a chronic phencyclidine (PCP) model of schizophrenia [24], and our data in Mecp2+/- mice parallels these findings. The gene discussed is MECP2; the disease is schizophrenia.